How Quitting Smoking Can Quickly Lower Risk Of A-Fib
Smokers who make the decision to quit will experience immediate health benefits, including a rapid reduction in their risk of atrial fibrillation (A-Fib), according to new research published in JACC: Clinical Electrophysiology. The study, conducted by Dr. Gregory Marcus, a cardiologist at the University of California, San Francisco, offers compelling evidence for smokers to quit, showing that it’s never too late to avoid the damaging effects of smoking on heart health.
Dr. Marcus, the senior author of the study, emphasized that A-Fib can be prevented even in individuals who have smoked for years. "The findings provide a compelling new reason to show current smokers that it’s not too late to quit, and that having smoked in the past doesn’t mean you’re ‘destined’ to develop A-Fib," Marcus explained. "Even for the current and longtime smoker, A-Fib can still be avoided."
"There’s strong evidence that smoking increases the risk of A-Fib," Marcus said. "But the benefits of quitting smoking have been less certain." With this in mind, his team sought to determine whether quitting could significantly lower a person’s risk of developing A-Fib, or if the risk would remain the same.
The research team analyzed data from over 146,700 current and former smokers, tracking their smoking habits and health over a 12-year period using data from the UK Biobank database. The results were promising: former smokers had a 13% lower risk of developing A-Fib compared to current smokers, while those who quit during the study saw an 18% reduction in their risk.
"This is likely a testament to the potency of reducing atrial fibrillation risk pretty shortly after quitting," Marcus said in a statement from the American College of Cardiology.
The findings highlight the importance of quitting smoking, not only for general health but specifically for reducing the risk of serious heart conditions like A-Fib.
Quitting smoking is one of the most effective ways to lower the risk of A-Fib and improve overall heart health. While it can be challenging, the benefits of quitting are clear and immediate. Here are some tips to help you quit smoking successfully:
1. Choose a specific date to quit smoking and stick to it. Prepare yourself mentally and physically for this change.
2. Reach out to family, friends, or a support group to help keep you accountable. Sharing your goals with others can provide encouragement.
3. Options like nicotine patches, gum, or lozenges can help ease withdrawal symptoms and reduce cravings.
4. Identify situations that make you want to smoke, such as stress or social gatherings, and find healthy ways to cope with them.
5. Regular exercise can help distract you from cravings and improve your mood during the quitting process.
6. Drinking water can help flush nicotine out of your system faster, reducing cravings.
7. Activities like yoga, meditation, or deep breathing exercises can help manage stress, a common trigger for smoking.
Quitting smoking offers immediate and significant benefits, particularly in reducing the risk of atrial fibrillation. The latest research provides smokers with more motivation to quit, showing that it's never too late to take control of their heart health.
Credit: HHS/X.com
The United States has reported 53 new measles cases, bringing the 2026 total to 2,371, according to the latest data from the Centers for Disease Control and Prevention (CDC).
Amid the rising outbreak, US Health Secretary Robert F. Kennedy Jr. urged American parents to vaccinate their children against the highly contagious disease.
The CDC said that of the 53 new cases, 16 were locally acquired across 45 US jurisdictions, while the remaining cases were linked to international travel.
Although measles is preventable through vaccination, the 2,371 cases reported as of July 30 have already surpassed the 2,289 cases recorded during all of 2025. Both years represent the highest annual measles totals in the US since 1991.
The US was declared measles-free in 2000, but it could lose that status later this year when the Pan American Health Organization reviews transmission data.
Also read: Donald Trump Urges RFK Jr. To Accelerate Childhood Vaccine Rollback
Read More: UK Woman Becomes World-First To Receive Experimental Cell Therapy For Ovarian Cancer
In a notable shift, Kennedy urged American parents to vaccinate their children against measles during a CNN interview.
Long known as a vaccine skeptic, Kennedy has spent years amplifying misinformation about vaccines, including the measles, mumps and rubella (MMR) vaccine. His remarks came as US measles cases surpassed the 2025 annual total.
The past two years have seen more measles infections in the US than the rest of the 21st century combined. More than 90% of cases have occurred in people who are unvaccinated or whose vaccination status is unknown.
"I've never questioned the efficacy of the MMR vaccine," the Healthy Secretary said.
Kennedy also blamed low vaccination rates in some religious communities for ongoing outbreaks.
"The communities that are suffering from measles are almost all religious communities that just don't vaccinate," Kennedy told CNN.
During the interview, Kennedy also blamed pandemic lockdowns on Dr. Anthony Fauci while repeating several widely debunked claims about vaccines and other health issues.
He claimed that respiratory syncytial virus (RSV) is a major cause of infant mortality, suggested Lyme disease was caused by laboratory manipulation of germs, repeated unsupported claims linking Tylenol use during pregnancy to autism, and questioned the effectiveness of COVID-19 vaccines for children.
Large studies conducted over several decades in multiple countries have consistently found no evidence that routine childhood vaccines cause autism.
Major medical associations also continue to consider acetaminophen the preferred pain reliever and fever reducer during pregnancy when used appropriately. They have also cautioned against avoiding acetaminophen altogether, noting that untreated high fever or severe pain during pregnancy can pose risks to both the mother and the developing baby.
Speaking to CNN, Ashish Jha, former White House COVID-19 response coordinator under President Joe Biden, said the rise in measles cases was not coincidental.
"The administration has not done enough to promote vaccines. It has not done enough to highlight the harms that come from measles."
Jha added that "accountability has to be with our political leaders," while criticizing Kennedy's false claims about vaccines.
Credit: The Christie's
A 58-year-old woman in the UK has become the first person in the world to receive an experimental cell therapy for ovarian cancer.
Tracy Tomlinson, who has been living with advanced ovarian cancer for more than five years, received the first dose of ZI-MA4-1 at The Christie NHS Foundation Trust as part of the ZIMA-101 clinical trial. The study is evaluating ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy to enter clinical development.
"While this is an early-stage study primarily focused on safety, it represents an exciting step forward in efforts to develop new treatment options for people like Tracy with advanced solid tumors. We hope the knowledge gained will help shape future cancer treatments and ultimately improve outcomes for patients," said Professor Fiona Thistlethwaite, consultant medical oncologist at The Christie.
Tracy, from Chadderton in Greater Manchester, was diagnosed with Stage 3C ovarian cancer shortly before Christmas 2020.
She first suspected something was wrong when what she thought was a urinary tract infection did not improve despite antibiotics prescribed by her GP. After blood tests, scans and further investigations, she was diagnosed with ovarian cancer just two days before her birthday.
Over the next several years, Tracy underwent surgery, multiple rounds of chemotherapy and maintenance therapy. By the summer of 2021, scans showed no evidence of disease, but the cancer returned a year later. She underwent further surgery and treatment, followed by additional recurrences.
Since 2023, Tracy has been living with ongoing cancer while receiving additional lines of treatment.
"The cancer is relentless," she said. "For me, it's never seemed to leave me alone."
Treatment has also caused fatigue, nausea and nerve damage in her hands and feet, eventually forcing her to stop working as a credit controller.
As her treatment options became more limited, Tracy began exploring clinical trials. Last year, she was referred to The Christie's early-phase clinical trials team and was eventually found eligible for the ZIMA-101 study.
After extensive screening, including scans, biopsies and blood tests, she became the first patient in the world to receive ZI-MA4-1.
"I decided almost straight away that I was going to go for it," she said. "Then afterwards you think, 'Am I doing the right thing?' because it is a little bit scary being the first person."
Following her first dose, Tracy remained in hospital for planned monitoring before being discharged on July 23.
"There are no guarantees with any trial," she said. "It could have a fantastic outcome, it could have no outcome, or somewhere in between. But if there is a possibility that it could work, I've got to go for it."
She added, "Cancer is no longer a death sentence. Five years ago, I thought I was going to die, but I'm still here."
Developed by Zelluna, ZI-MA4-1 combines two immune-based approaches to target cancer. The therapy uses natural killer (NK) cells, which can detect and destroy abnormal cells, together with engineered T-cell receptors (TCRs) that enable them to recognize tumors expressing the protein MAGE-A4.
MAGE-A4 is found in several solid tumors, including ovarian cancer, making it a promising target for precision cancer therapies.
Unlike personalized cell therapies that require a patient's own cells to be collected and manufactured individually, ZI-MA4-1 uses donor-derived immune cells and is designed as an "off-the-shelf" treatment.
Researchers hope this approach could make advanced cell therapies available to more patients in less time.
Credit: AI
Reducing sugar intake during pregnancy and the first two years of a child’s life could have life-changing benefits for brain health, particularly in lowering the risk of Alzheimer’s disease.
According to a new study, limiting sugar intake could reduce the risk Alzheimer’s by more than 45% in the future.
The research, published in npj Aging, found that people exposed to lower sugar intake during the first 1,000 days of life, from conception until age two, had a 46% lower risk of Alzheimer’s disease, a 27% lower risk of dementia, an 11% lower risk of depression, and a 20% lower risk of anxiety in later life.
Researchers analysed health and brain imaging data from more than 60,000 participants in the UK Biobank.
They used Britain’s World War II sugar rationing period as a natural experiment, comparing people born when sugar availability was restricted with those born after rationing ended.
Scientists say that early life is a critical phase for the brain, metabolism, and immune system. Nutrition during this period can shape long-term health, influencing disease risk of neurodegenerative disease decades later.
“Our findings suggest that limiting sugar intake during the first 1,000 days of life may have long-lasting benefits for brain health,” the researchers noted, adding that the effects appear to persist well into older adulthood.
Dr. Bing Zhang, a geriatric medicine researcher involved in the study, said the results support the idea that nutrition in early life can shape lifelong brain health through metabolic programming during critical stages of development.
The study also found key structural differences in the brain. MRI scans showed that participants who had lower sugar exposure early in life had brains that appeared approximately 0.4 years younger biologically.
Their brains showed greater grey matter volume and fewer signs of white matter damage that is often linked to healthier cognitive ageing.
The researchers found an association, not proof that sugar directly causes Alzheimer’s or dementia. Since the study is observational, other factors like overall diet, access to healthcare facilities and services, and lifestyle may also have contributed to the findings.
Dr. Sara Rodrigues of Alzheimer’s Research UK, who was not involved in the research, cautioned that while the results are compelling, they do not establish cause and effect. However, they add to the growing evidence that healthy eating throughout life plays an important role in maintaining brain health.
This comes after a recent study suggested that children who who consume higher amounts of ultra-processed foods may already be showing subtle changes in the way their bodies regulate insulin, potentially increasing the risk for type 2 diabetes in the future.
According to a new study published in the journal Nutrients, children who have higher amounts of in ultra-processed foods (UPFs) had reduced insulin sensitivity and higher insulin secretion, even though they did not have diabetes.
Researchers from Texas A&M University–San Antonio, University of Texas Health San Antonio, University of Texas Rio Grande Valley, and Wake Forest University School of Medicine discovered that the metabolic changes linked to diabetes may begin much earlier in life than previously thought.
© 2024 Bennett, Coleman & Company Limited